The potential for selective pharmacological therapies through biased receptor signaling

41Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The discovery that not all agonists uniformly activate cellular signaling pathways (biased signaling) has greatly changed the drug discovery process for agonists and the strategy for treatment of disease with agonists. Technological advances have enabled complex receptor behaviors to be viewed independently and through these assays, the bias for an agonist can be quantified. It is predicted that therapeutic phenotypes will be linked, through translational studies, to quantified scales of bias to guide medicinal chemists in the drug discovery process. © 2012 Kenakin; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Kenakin, T. (2012, August 13). The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-13-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free